True Vision MN’s Gilead Sciences GILD Stock Holding History

True Vision MN’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$622K	Buy	+4,464	New	+$625K	0.32%	59

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

True Vision MN's GILD Position: Q1 2026 in Review

True Vision MN opened a new position in Gilead Sciences (GILD) in Q1 2026: 4,464 shares worth $622K. The stake represents 0.32% of the portfolio and ranks #59 among its holdings.

2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

True Vision MN held 4,464 shares of Gilead Sciences worth $622K as of Q1 2026.
Gilead Sciences was a new True Vision MN position in Q1 2026.
Gilead Sciences made up 0.32% of True Vision MN's portfolio in Q1 2026, its #59 holding.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on True Vision MN's 13F filing for Q1 2026, filed 16 Apr 2026.